Phase 2 N=406 Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Phase 2 N=140 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Phase 2 N=51 Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
N/A N=49 Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Breast Cancer Metastases · HER2 Positive Breast
Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 2 N=56 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
N/A N=580 An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
Phase 2 N=49 Neoadjuvant GW572016 to Treat Breast Cancer
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants
Phase 2 N=31 Cardiac Safety Study in Patients With HER2 + Breast Cancer
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Phase 2 N=136 Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Breast Neoplasms · Neoplasms
Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants
N/A N=30 Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples
Breast Cancer
Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 2 N=24 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 2 N=50 An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Breast Neoplasms
Primary: Objective Response (OR) — 0 Participants with OR
Phase 3 N=736 A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 8.0; 8.7; 8.8 Months — p=0.0318
Phase 2 N=100 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 2 N=173 Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Phase 2 N=20 Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
HER2 Positive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…
N/A N=367 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
Phase 2 N=58 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants
Phase 2 N=32 Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Breast Cancer
Primary: Pathologic Complete Response — 26 percentage of participants
Phase 2 N=275 Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Breast Cancer
Primary: Disease-free Survival (DFS) — 89.8; 83.8 Percentage of participants who survived — p=0.18
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants